Can afamelanotide and glucagon be used together?

Yes, in principle. A patient with both EPP and diabetes could use afamelanotide for sun protection and carry glucagon for hypoglycemic emergencies. These compounds target different physiological systems and aren't known to interact. However, such a patient would need close medical supervision given the rarity of EPP and the complexity of dual therapy.

Why does glucagon have so many more clinical trials than afamelanotide?

Glucagon has been in clinical use since the 1950s and is used worldwide across multiple formulations and indications. Afamelanotide is newer (approved 2014) and approved for a single rare condition, so its development program is more focused. Trial count reflects clinical history and usage breadth, not necessarily efficacy.

Is afamelanotide available outside the US and EU?

Afamelanotide (Scenesse®) is FDA-approved in the US and EMA-authorised in Europe. It is not approved by Health Canada. Availability in other countries depends on local regulatory pathways. Glucagon, by contrast, is approved in all three major markets (US, EU, Canada).

What are the most common side effects of each?

Afamelanotide commonly causes mild nausea during the first days after implant insertion and progressive darkening of existing moles. Glucagon can cause nausea, headache, and transient hyperglycemia (high blood sugar) after injection. Both are generally well-tolerated.

Could afamelanotide help with other types of photosensitivity?

Afamelanotide is specifically approved for erythropoietic protoporphyria. While [clinical research has explored its potential in other photosensitive porphyrias](https://pubmed.ncbi.nlm.nih.gov/19505557), it is not approved for these uses. Off-label use would require a physician's judgment and patient informed consent.

Afamelanotide vs Glucagon: Key Differences & Uses

Afamelanotide and glucagon are both FDA-approved peptides, but they work in completely different ways and treat unrelated conditions. Glucagon is a hormone that raises blood sugar rapidly—it's been in clinical use for decades and has over 1,000 clinical trials backing its safety profile. Afamelanotide is a melanocyte-stimulating hormone (MSH) analogue approved for a rare genetic skin condition called erythropoietic protoporphyria (EPP). While both are peptides and both are regulatory-approved, comparing them is a bit like comparing insulin to growth hormone: they're in different therapeutic worlds. This guide breaks down what each does, how the research stacks up, and who actually needs each one.

What Is Afamelanotide?

Afamelanotide is a synthetic alpha-melanocyte-stimulating hormone (α-MSH) analogue that stimulates melanin production in the skin. It's approved by both the FDA and EMA specifically for erythropoietic protoporphyria (EPP), a rare genetic disorder where the body accumulates toxic porphyrins in red blood cells and skin. These accumulate cause severe photosensitivity—exposure to sunlight triggers extreme pain and blistering.

Afamelanotide works by binding to melanocortin-1 receptors on melanocytes, increasing melanin synthesis. This darker skin provides a natural protective barrier against sun damage. The peptide is administered as a subcutaneous implant (a small rod placed under the skin) that releases the medication steadily over about 60 days.

Clinical Evidence for Afamelanotide

Afamelanotide's approval is backed by 23 registered clinical trials exploring its use in EPP and other photosensitive conditions. The pivotal trial demonstrated that patients using afamelanotide implants experienced significant improvements in sun tolerance and quality of life, with measurable increases in skin pigmentation.

A key Phase 3 trial published in JAMA Dermatology showed that afamelanotide, combined with sun protection, reduced the phototoxic reactions and pain episodes in EPP patients compared to placebo. Safety data from these trials showed the compound is well tolerated, with the most common side effects being mild darkening of existing moles and nausea during the implant period.

What Is Glucagon?

Glucagon is a 29-amino-acid peptide hormone produced naturally by the pancreas (alpha cells) that raises blood glucose levels. Unlike afamelanotide, glucagon has a decades-long history in medicine and is used as an acute emergency treatment for severe hypoglycemia (dangerously low blood sugar).

Glucagon works by binding to glucagon receptors on liver and muscle cells, triggering the breakdown of stored glycogen into glucose and accelerating gluconeogenesis (the production of new glucose). This rapid glucose release can reverse hypoglycemia within minutes—critical when a diabetic patient loses consciousness or can't eat.

Clinical Evidence for Glucagon

Glucagon is one of the most extensively studied peptides in history, with over 1,000 clinical trials registered. The compound has been FDA-approved since the 1950s, and its safety and efficacy are well-established across multiple formulations: traditional powder-and-solvent kits, liquid-filled auto-injectors (GlucaGon, Gvoke), and nasal sprays (Baqsimi).

Landmark studies confirm glucagon reverses severe hypoglycemia within 5–15 minutes in the majority of cases, making it a life-saving emergency medication. Approved in the US, EU, and Canada, glucagon is part of standard diabetic emergency protocols worldwide.

Key Differences

Mechanism of Action

Afamelanotide stimulates melanin production via melanocortin-1 receptor activation. It's a hormone analogue designed to mimic a natural signaling pathway involved in skin pigmentation.

Glucagon triggers hepatic glucose release via glucagon receptor signaling. It's a counter-regulatory hormone that opposes insulin.

Therapeutic Purpose

Afamelanotide is for a rare genetic skin condition (EPP) where patients cannot tolerate sunlight due to toxic porphyrin accumulation. It's not an emergency drug—it's a preventive treatment given regularly to build protective pigmentation.

Glucagon is for acute, life-threatening hypoglycemia. It's an emergency medication, not a chronic treatment. Diabetics carry it "just in case."

Route of Administration

Afamelanotide is a subcutaneous implant placed every 60 days. It provides steady, long-acting hormone delivery.

Glucagon is typically injected intramuscularly or given as a nasal spray during emergencies. It acts fast but acutely.

Regulatory Status

Afamelanotide:

✅ FDA-approved (2014)
✅ EMA-authorised (Scenesse®)
❌ Not approved in Canada

Glucagon:

✅ FDA-approved (since 1950s, multiple formulations)
✅ EMA-authorised
✅ Health Canada approved

Patient Population

Afamelanotide patients are those with documented erythropoietic protoporphyria or other rare photosensitive porphyrias. It's a niche medication for a specific genetic condition affecting perhaps 1 in 500,000 people globally.

Glucagon is prescribed to anyone with insulin-dependent diabetes or other conditions prone to severe hypoglycemia—millions of people worldwide.

Research Quality & Evidence Grading

Both compounds carry an A-grade evidence classification in regulatory systems, meaning they've completed rigorous clinical trials and have demonstrated efficacy and safety.

Afamelanotide's 23 trials are concentrated on EPP and photosensitive conditions, with a focused clinical development program.
Glucagon's 1,000+ trials span decades and cover hypoglycemia reversal, acute medical use, diagnostic applications, and newer formulations. This breadth of evidence reflects its long clinical history and broader applications.

Who Should Use Each?

Afamelanotide Is For:

Patients with confirmed erythropoietic protoporphyria (genetic diagnosis required)
Those who experience severe photosensitivity and want to expand their sun tolerance
Patients seeking a preventive approach to a chronic photosensitive condition
People willing to use a subcutaneous implant device

Glucagon Is For:

Type 1 diabetics on insulin who are at risk of severe hypoglycemia
Type 2 diabetics on insulin or sulfonylureas experiencing hypoglycemic episodes
Anyone at risk of unconsciousness due to low blood sugar
Emergency responders and caregivers of diabetics (many glucagon kits are prescribed for others to administer)

Clinical Distinctions

Afamelanotide addresses a rare genetic condition and represents a novel therapeutic approach—using the body's natural pigmentation response to provide photoprotection. Glucagon is a classical hormone replacement therapy used acutely to reverse a metabolic emergency.

Afamelanotide requires a diagnostic workup and genetic confirmation of EPP; it's a specialist prescription. Glucagon is widely prescribed by primary care physicians and endocrinologists as standard diabetes care.

Both are peptide-based, both are approved by major regulatory agencies, and both have strong clinical evidence. But they occupy entirely different niches in medical practice.

The Bottom Line

These are two approved peptides solving completely different problems. If you have EPP and photosensitivity, afamelanotide may significantly improve your quality of life. If you have diabetes and risk of severe hypoglycemia, glucagon could be life-saving. They're not competitors—they're treatments for separate patient populations with separate medical needs.

Curious about other peptide treatments? Or want to understand how melanocyte-stimulating hormones work? Explore the PeptideTrace database for more information on approved and investigational peptides.

Afamelanotide vs Glucagon: Understanding Two Very Different Peptides